한글목차

Zuranolone(SAGE-217)은 산후우울증(PPD) 치료제로 개발중인 경구용 신약으로, 1일 1회 2주간 투여하는 신경활성스테로이드(NAS) GABAA 수용체 양성 동종조절제(PAM)로 PPD, 주요우울장애(MDD), 치료 저항성 우울증을 포함한 여러 우울장애를 완화하기 위해 특별히 고안된 약물입니다. GABA 시스템은 뇌의 주요 억제성 신호 전달 경로이며 중추 신경계(CNS)는 CNS 기능을 현저하게 조절합니다. SAGE-217은 시냅스 및 시냅스 외 A형 γ- 아미노 부티르산(GABAA) 수용체에 대한 선택성과 1,000 개의(GABAA) 수용체에 대한 선택성과 1일 1회 경구 투여에 적합한 약동학적 프로파일에 최적화되어 있습니다.

앞으로 수년간 산후우울증(PPD) 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, SAGE-217의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, PPD에 대한 다른 신흥 제품이 SAGE-217과 치열한 시장 경쟁을 벌일 것으로 예상됩니다, 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

미국의 SAGE-217 시장에 대해 조사했으며, 산후 우울증(PPD) 치료제인 SAGE-217 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 산후 우울증(PPD)에 대한 SAGE-217의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 SAGE-217 시장 평가

• PPD에 대한 SAGE-217의 시장 전망
• 미국의 분석
  • 미국에서 PPD에 대한 SAGE-217의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"SAGE-217 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SAGE-217 for Postpartum depression (PPD) in the United States. A detailed picture of the SAGE-217 for PPD in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the SAGE-217 for PPD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAGE-217 market forecast analysis for PPD in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PPD.

Drug Summary:

Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type A γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SAGE-217 description, mechanism of action, dosage and administration, research and development activities in postpartum depression (PPD).
• Elaborated details on SAGE-217 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SAGE-217 research and development activities in PPD across the United States.
• The report also covers the patents information with expiry timeline around SAGE-217.
• The report contains forecasted sales of SAGE-217 for PPD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PPD.
• The report also features the SWOT analysis with analyst views for SAGE-217 in PPD.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAGE-217 Analytical Perspective by DelveInsight

In-depth SAGE-217 Market Assessment

This report provides a detailed market assessment of SAGE-217 for postpartum depression (PPD) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

SAGE-217 Clinical Assessment

The report provides the clinical trials information of SAGE-217 for PPD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for postpartum depression (PPD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAGE-217 dominance.
• Other emerging products for PPD are expected to give tough market competition to SAGE-217 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAGE-217 in PPD.
• Our in-depth analysis of the forecasted sales data of SAGE-217 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAGE-217 in PPD.

Key Questions:

• What is the product type, route of administration and mechanism of action of SAGE-217?
• What is the clinical trial status of the study related to SAGE-217 in postpartum depression (PPD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAGE-217 development?
• What are the key designations that have been granted to SAGE-217 for PPD?
• What is the forecasted market scenario of SAGE-217 for PPD?
• What are the forecasted sales of SAGE-217 in the United States?
• What are the other emerging products available and how are these giving competition to SAGE-217 for PPD?
• Which are the late-stage emerging therapies under development for the treatment of PPD?

Table of Contents

1. Report Introduction

2. SAGE-217 Overview in PPD

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SAGE-217 Market Assessment

• 5.1. Market Outlook of SAGE-217 in PPD
• 5.2. The United States Analysis
  • 5.2.1. Market Size of SAGE-217 in the United States for PPD

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options